Business
The Opthea (ASX:OPT) share price up after receiving FDA approval
The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.
Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market.
Another milestone for the Opthea share price
An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the…
-
Business20 hours agoZip shares rocketed 32% in August. Here’s how
-
Business22 hours agoGold price alert! Macquarie reveals its top ASX 200 gold stock as the metal hits all-time high
-
Business18 hours agoDown more than 20% this year, does Macquarie rate Boss Energy shares a buy?
-
General20 hours agoKids unknowingly targeted with AI abuse apps, images